Company: IMRX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001790340-25-000135
Chunk: 335

Company: Immuneering Corp
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 335
---
 2024— — Additional paid-in capital496,653,023 265,650,362 Accumulated deficit(268,740,074)(224,295,186)Total stockholders' equity227,976,432 41,386,226 Total liabilities and stockholders' equity$241,056,266 $52,714,413 

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

7

Table of Contents

IMMUNEERING CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

Three Months Ended September 30,Nine Months Ended September 30,2025202420252024Operating expensesResearch and development$10,867,983 $11,252,850 $32,793,835 $33,107,222 General and administrative4,505,406 4,013,581 12,807,465 12,384,074 Amortization of intangible asset7,317 7,317 21,950 21,950 Total operating expenses15,380,706 15,273,748 45,623,250 45,513,246 Loss from operations(15,380,706)(15,273,748)(45,623,250)(45,513,246)Other income (expense)Interest income415,831 547,072 1,178,362 2,178,060 Other income, net— 129,310 — 350,063 Net loss$(14,964,875)$(14,597,366)$(44,444,888)$(42,985,123)Net loss per share attributable to common stockholders, basic and diluted$(0.38)$(0.49)$(1.20)$(1.45)Weighted-average common shares outstanding, basic and diluted39,670,09529,841,88337,077,04129,622,670Other comprehensive loss:Unrealized loss from marketable securities— 7,845 — 8,624 Comprehensive Loss$(14,964,875)$(14,589,521)$(44,444,888)$(42,976,499)

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

8

Table of Contents

IMMUNEERING CORPORATION

CONDENSED CONSOLIDATED STATE